Review

kcl22 s acc519 cell lines (DSMZ)

DSMZ is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

DSMZ kcl22 s acc519 cell lines
Kcl22 S Acc519 Cell Lines, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 71 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/kcl22 s acc519 cell lines/product/DSMZ
Average 93 stars, based on 71 article reviews

kcl22 s acc519 cell lines - by Bioz Stars, 2026-06

93/100 stars

Images

Image Search Results

CML‐derived cell lines. In particular, name of cell line, cell type, sex and age of patient at time of establishment of cell line, disease status, year of establishment of cell line, source of specimen as indicated in the original publication and type of BCR,ABL1 fusion are indicated (BC = blastic crisis, BCP = B‐Cell Precursor, B‐LCL = B‐lymphoblastoid cell line (EBV + ), BM = bone marrow, BMT = bone marrow transplantation, F = female, M = male, NA = not available, R = relapse, PB = peripheral blood, PE = pleural effusion).

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: CML‐derived cell lines. In particular, name of cell line, cell type, sex and age of patient at time of establishment of cell line, disease status, year of establishment of cell line, source of specimen as indicated in the original publication and type of BCR,ABL1 fusion are indicated (BC = blastic crisis, BCP = B‐Cell Precursor, B‐LCL = B‐lymphoblastoid cell line (EBV + ), BM = bone marrow, BMT = bone marrow transplantation, F = female, M = male, NA = not available, R = relapse, PB = peripheral blood, PE = pleural effusion).

Article Snippet: This observation can be attributed to the fact that the KCL22 cell line has a faster doubling time (24 h) compared to K562 and LAMA84 (35 h and 50 h, respectively) ( https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-168 ; https://www.Dsmz.de/Collection/Catalogue/Details/Culture/ACC-519 ; https://www.Sigmaaldrich.Com/IT/It/Product/Sigma/Cb_89121407 ).

Techniques: Transplantation Assay

Panel of images illustrating the seven different treatment conditions of K562, LAMA84, and KCL22 cell lines obtained using the Invitrogen EVOS XL Core Imaging System with a 20× zoom. Areas of the well that best showed the cellular conditions were selected (including color, shape, size, and the formation of dead cell clusters). Panel A1, A2, A3: Control at 20× zoom in the three cell lines; Panel B1, B2, B3: DMSO at 20X zoom in the three cell lines; Panel C1, C2, C3: imatinib at 20× zoom in the three cell lines; Panel D1, D2, D3: nilotinib at 20× zoom in the three cell lines; Panel E1, E2, E3: dasatinib at 20× zoom in the three cell lines; Panel F1, F2, F3: bosutinib at 20× zoom in the three cell lines; Panel G1, G2, G3: ponatinib at 20× zoom in the three cell lines. Red arrows indicate significantly larger sized cells; blue arrow indicate cell clusters; orange arrows indicate larger sized cells; green arrows indicate irregularly shaped cells; blue boxes highlight apoptotic bodies. (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib).

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Panel of images illustrating the seven different treatment conditions of K562, LAMA84, and KCL22 cell lines obtained using the Invitrogen EVOS XL Core Imaging System with a 20× zoom. Areas of the well that best showed the cellular conditions were selected (including color, shape, size, and the formation of dead cell clusters). Panel A1, A2, A3: Control at 20× zoom in the three cell lines; Panel B1, B2, B3: DMSO at 20X zoom in the three cell lines; Panel C1, C2, C3: imatinib at 20× zoom in the three cell lines; Panel D1, D2, D3: nilotinib at 20× zoom in the three cell lines; Panel E1, E2, E3: dasatinib at 20× zoom in the three cell lines; Panel F1, F2, F3: bosutinib at 20× zoom in the three cell lines; Panel G1, G2, G3: ponatinib at 20× zoom in the three cell lines. Red arrows indicate significantly larger sized cells; blue arrow indicate cell clusters; orange arrows indicate larger sized cells; green arrows indicate irregularly shaped cells; blue boxes highlight apoptotic bodies. (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib).

Techniques: Imaging, Control

The average area, diameter, and circularity resulting from each treatment in the three cell lines utilized. Values that have shown statistically significant differences during comparison are highlighted in green. (BOSU, bosutinib; CTR, control; DASA, dasatinib; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; PONA, ponatinib; TKIs, tyrosine kinase inhibitors). (Two Way ANOVA).

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: The average area, diameter, and circularity resulting from each treatment in the three cell lines utilized. Values that have shown statistically significant differences during comparison are highlighted in green. (BOSU, bosutinib; CTR, control; DASA, dasatinib; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; PONA, ponatinib; TKIs, tyrosine kinase inhibitors). (Two Way ANOVA).

Techniques: Comparison, Control

Cells viability (%) measured by MTT assay in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Cells viability (%) measured by MTT assay in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Techniques: MTT Assay, Comparison, Control

Number of cells measured by CCK8 assay in the three cell lines considered, K562, LAMA84 and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Number of cells measured by CCK8 assay in the three cell lines considered, K562, LAMA84 and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Techniques: CCK-8 Assay, Comparison, Control

Extracellular glutamate concentration (μM) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA: imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Extracellular glutamate concentration (μM) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA: imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Techniques: Concentration Assay, Comparison, Control

Expression of BCR::ABL1 transcript (normalised for GAPDH) in the three cell lines considered, K562, LAMA84 and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Expression of BCR::ABL1 transcript (normalised for GAPDH) in the three cell lines considered, K562, LAMA84 and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Techniques: Expressing, Comparison, Control

Expression of CD33 transcript (normalized for GAPDH) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Expression of CD33 transcript (normalized for GAPDH) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Techniques: Expressing, Comparison, Control

Expression of CD11b transcript (normalized for GAPDH) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Expression of CD11b transcript (normalized for GAPDH) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).

Techniques: Expressing, Comparison, Control

Panel of images illustrating asciminib treatment of K562, LAMA84, and KCL22 cell lines obtained using the Invitrogen EVOS XL Core Imaging System with a 20× zoom. Areas of the well that best showed the cellular conditions were selected (including color, shape, size, and the formation of dead cell clusters). Panel A1, A2, A3: Control at 20× zoom in the three cell lines; Panel B1, B2, B3: asciminib at 20× zoom in the three cell lines. Red arrows indicate significantly larger sized cells; blue arrow indicate cell clusters; orange arrows indicate larger sized cells; green arrows indicate irregularly shaped cells. (CTR, control; ASCI, asciminib).

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Panel of images illustrating asciminib treatment of K562, LAMA84, and KCL22 cell lines obtained using the Invitrogen EVOS XL Core Imaging System with a 20× zoom. Areas of the well that best showed the cellular conditions were selected (including color, shape, size, and the formation of dead cell clusters). Panel A1, A2, A3: Control at 20× zoom in the three cell lines; Panel B1, B2, B3: asciminib at 20× zoom in the three cell lines. Red arrows indicate significantly larger sized cells; blue arrow indicate cell clusters; orange arrows indicate larger sized cells; green arrows indicate irregularly shaped cells. (CTR, control; ASCI, asciminib).

Techniques: Imaging, Control

The average area, diameter, and circularity resulting from asciminib treatment in the three cell lines utilized. Values that have shown statistically significant differences during comparison are highlighted in green. (ASCI, asciminib; CTR, control). (Two Way ANOVA).

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: The average area, diameter, and circularity resulting from asciminib treatment in the three cell lines utilized. Values that have shown statistically significant differences during comparison are highlighted in green. (ASCI, asciminib; CTR, control). (Two Way ANOVA).

Techniques: Comparison, Control

Cell viability (%) measured by MTT assay (A), number of cells measured by CCK8 assay (B), extracellular glutamate concentration (μM) (C) and expression of BCR::ABL1 (D), CD33 (E) and CD11b (F) transcripts all normalized for GAPDH in the three cell lines considered, K562, LAMA84 and KCL22, following asciminib treatment. (CTR, control; ASCI, asciminib) (Two‐way ANOVA with Tukey's post hoc test).

Journal: Cell Biology International

Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

doi: 10.1002/cbin.70007

Figure Lengend Snippet: Cell viability (%) measured by MTT assay (A), number of cells measured by CCK8 assay (B), extracellular glutamate concentration (μM) (C) and expression of BCR::ABL1 (D), CD33 (E) and CD11b (F) transcripts all normalized for GAPDH in the three cell lines considered, K562, LAMA84 and KCL22, following asciminib treatment. (CTR, control; ASCI, asciminib) (Two‐way ANOVA with Tukey's post hoc test).

Techniques: MTT Assay, CCK-8 Assay, Concentration Assay, Expressing, Control

Fig. 2 Transcriptomic (RNA-sequencing) and quantitative mass spectrometry (MS)-based proteomic analysis of HSP90α/β-KO cells. A Volcano plot showing signiﬁcantly (FDR <0.05; log2(FC) < −1 or log2(FC) > 1, calculated using edgeR (F-Test & Benjamini-Hochberg correction) up- or down-regulated genes from RNA-sequencing data (obtained from three independent replicates) of HSP90α-KO compared to empty vector (EV) control K562 cells. Black dots represent genes that are not signiﬁcantly regulated, while gray dots represent signiﬁcantly regulated genes, but below log2(FC) threshold. Blue and red dots represent signiﬁcantly downregulated and upregulated genes, respectively. B fGSEA on the RNA-seq data of HSP90β-KO cells, displaying signiﬁcantly (FDR = 0.05) regulated ontology gene set signatures in comparison to EV control. C Volcano plot obtained from ﬁve independent replicates of HSP90α-KO compared to EV control K562 cells showing up- or down-regulated proteins based on MS-based proteomics data applying p-value < 0.05 and log2(FC) < −1 or log2(FC) > 1 as the speciﬁcity cutoff criteria. D Gene clusters obtained using clusterProﬁler on the MS data of HSP90α-KO cells revealed signiﬁcant downregulation (FDR = 0.05) of energy metabolism signature. Normalized enrichment scores (NES). Tables showing consistently up- or down-regulated genes in HSP90α-KO (E) or in HSP90β-KO (F) K562 cells from the RNA-seq and MS-based proteomics analysis.

Journal: Cell death & disease

Article Title: Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.

doi: 10.1038/s41419-023-06337-3

Figure Lengend Snippet: Fig. 2 Transcriptomic (RNA-sequencing) and quantitative mass spectrometry (MS)-based proteomic analysis of HSP90α/β-KO cells. A Volcano plot showing signiﬁcantly (FDR <0.05; log2(FC) < −1 or log2(FC) > 1, calculated using edgeR (F-Test & Benjamini-Hochberg correction) up- or down-regulated genes from RNA-sequencing data (obtained from three independent replicates) of HSP90α-KO compared to empty vector (EV) control K562 cells. Black dots represent genes that are not signiﬁcantly regulated, while gray dots represent signiﬁcantly regulated genes, but below log2(FC) threshold. Blue and red dots represent signiﬁcantly downregulated and upregulated genes, respectively. B fGSEA on the RNA-seq data of HSP90β-KO cells, displaying signiﬁcantly (FDR = 0.05) regulated ontology gene set signatures in comparison to EV control. C Volcano plot obtained from ﬁve independent replicates of HSP90α-KO compared to EV control K562 cells showing up- or down-regulated proteins based on MS-based proteomics data applying p-value < 0.05 and log2(FC) < −1 or log2(FC) > 1 as the speciﬁcity cutoff criteria. D Gene clusters obtained using clusterProﬁler on the MS data of HSP90α-KO cells revealed signiﬁcant downregulation (FDR = 0.05) of energy metabolism signature. Normalized enrichment scores (NES). Tables showing consistently up- or down-regulated genes in HSP90α-KO (E) or in HSP90β-KO (F) K562 cells from the RNA-seq and MS-based proteomics analysis.

Article Snippet: BCR-ABL1+ chronic myeloid leukemia (CML) cell lines K562, KCL22 and B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cell line SUPB15 (DSMZ, Braunschweig, Germany) were cultured in RPMI1640 GlutaMAX (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10–15% FCS and 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA).

Techniques: RNA Sequencing, Mass Spectrometry, Plasmid Preparation, Control, Comparison

Fig. 4 Resistance against HSP90i PU-H71 is attained by HSP90α overexpression. A Schematic depiction of the workﬂow of generating HSP90 inhibitor (HSP90i) resistant cells, through chronic exposure of HSP90-N-terminal domain- (PU-H71 and Tanespimycin or TM) or HSP90- C-terminal domain-targeting (Coumermycin A1 or CA1) inhibitors in K562 cells. B Dose–response curves from three independent experiments showing signiﬁcant (***p ≤0.001, unpaired two-tailed student’s t-test) increase in IC50 values for PU-H71-resistant (PUHr) and CA1-resistant (CA1r) cells in comparison to their parental (P) counterparts. C Cross-resistance of PUHr and CA1r cells to other HSP90i with similar or different modes of action (MoA). The numbers in the heat map indicate the normalized fold-change of the IC50 values of the resistant cell lines to the parental counterpart. The red color depicts an increase in IC50 value whereas green indicates a decrease in IC50 value in comparison to the parental control. D WB analysis of PUHr, CA1r and control parental (P) cells after re-treatment with CA1 (2 µM), PU-H71 (500 nM) or vehicle (-) for 24 h. GAPDH served as a loading control.

Journal: Cell death & disease

Article Title: Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.

doi: 10.1038/s41419-023-06337-3

Figure Lengend Snippet: Fig. 4 Resistance against HSP90i PU-H71 is attained by HSP90α overexpression. A Schematic depiction of the workﬂow of generating HSP90 inhibitor (HSP90i) resistant cells, through chronic exposure of HSP90-N-terminal domain- (PU-H71 and Tanespimycin or TM) or HSP90- C-terminal domain-targeting (Coumermycin A1 or CA1) inhibitors in K562 cells. B Dose–response curves from three independent experiments showing signiﬁcant (***p ≤0.001, unpaired two-tailed student’s t-test) increase in IC50 values for PU-H71-resistant (PUHr) and CA1-resistant (CA1r) cells in comparison to their parental (P) counterparts. C Cross-resistance of PUHr and CA1r cells to other HSP90i with similar or different modes of action (MoA). The numbers in the heat map indicate the normalized fold-change of the IC50 values of the resistant cell lines to the parental counterpart. The red color depicts an increase in IC50 value whereas green indicates a decrease in IC50 value in comparison to the parental control. D WB analysis of PUHr, CA1r and control parental (P) cells after re-treatment with CA1 (2 µM), PU-H71 (500 nM) or vehicle (-) for 24 h. GAPDH served as a loading control.

Techniques: Over Expression, Two Tailed Test, Comparison, Control

Review

Structured Review

Images

Similar Products

Image Search Results